Johns Hopkins University

Bristol-myers Squibb Compnay

Sachin S Chandran

Martin Gilbert Pomper

Ronnie Charles Mease

Sangeeta Ray

Samuel Ray Denmeade

Robert K Perrone

Krishnaswamy Srinivas Raghavan

Ismat Ullah

Christopher P Price

Rajesh Babulal Gandhi

Jaquan Kalani Levons

The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.

Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer

Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.

Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Growing community of inventors

Highland Park, NJ, United States of America

Sachin S Chandran